Most weight loss achieved using injectable obesity drugs can be maintained by switching to orforglipron, study shows

New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) and published in Nature Medicine shows that most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment.